Defining phenotypic and functional heterogeneity of glioblastoma stem cells by mass cytometry

Most patients with glioblastoma (GBM) die within 2 years. A major therapeutic goal is to target GBM stem cells (GSCs), a subpopulation of cells that contribute to treatment resistance and recurrence. Since their discovery in 2003, GSCs have been isolated using single-surface markers, such as CD15, C...

Descripción completa

Detalles Bibliográficos
Autores principales: Galdieri, Luciano, Jash, Arijita, Malkova, Olga, Mao, Diane D., DeSouza, Patrick, Chu, Yunli E., Salter, Amber, Campian, Jian L., Naegle, Kristen M., Brennan, Cameron W., Wakimoto, Hiroaki, Oh, Stephen T., Kim, Albert H., Chheda, Milan G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934942/
https://www.ncbi.nlm.nih.gov/pubmed/33400685
http://dx.doi.org/10.1172/jci.insight.128456